Baidu
map

药监局修订说明书!万通筋骨片其实不万能

2018-09-24 孙欢 健康时报网

“腰腿痛,风湿病,请服万通筋骨片。一般人我不告诉他!”这是大家耳熟能详的广告语,很多老人筋骨不舒服了,就习惯性买来吃,但其实万通筋骨片并不万能。9月5日,国家药品监督管理局发布公告,决定对万通筋骨片说明书“不良反应”“禁忌”和“注意事项”进行修订。“禁忌”中指出婴幼儿禁用,“注意事项”也指明,出现不良反应时要及时就医且不宜长期使用。处方药,不宜长期使用尽管广告大家耳熟能详,但事实上万通筋骨片属于

“腰腿痛,风湿病,请服万通筋骨片。一般人我不告诉他!”

这是大家耳熟能详的广告语,很多老人筋骨不舒服了,就习惯性买来吃,但其实万通筋骨片并不万能。

9月5日,国家药品监督管理局发布公告,决定对万通筋骨片说明书“不良反应”“禁忌”和“注意事项”进行修订。“禁忌”中指出婴幼儿禁用,“注意事项”也指明,出现不良反应时要及时就医且不宜长期使用。

处方药,不宜长期使用

尽管广告大家耳熟能详,但事实上万通筋骨片属于处方药。

吉林万通药业集团官网显示,万通筋骨片的主要成分为制川乌、制草乌、制马钱子、细辛、牛膝、羌活等,主要作用于祛风散寒,通络止痛。用于痹症,腰腿痛,肌肉关节疼痛,屈伸不利,以及肩周炎、颈椎病、风湿性关节炎、类风湿性关节炎等疾病。

在2015版《中华人民共和国药典》中,万通筋骨片成分中的制川乌、制草乌、制马钱子在“性味与归经”项目均注明了“有毒”和“有大毒”。

而细辛中的马兜铃酸更是具有明显肾毒性,可造成肾小管功能受损,更严重的甚至存在引发肾癌的风险。2002年,世界卫生组织(WHO)国际癌症研究机构将马兜铃酸列为一种潜在的致癌物质,2012年将其列入I类致癌物质。

“制川乌、制草乌、制马钱子这类含有‘制’字的中药都是经过加工的,毒性都有所减轻,但长期大量使用马钱子、细辛可能会存在肝肾风险。”浙江中医医院骨科中心主任童培建介绍道。

而在万通筋骨片的说明书中,其不良反应一栏却直接写着“不良反应尚未明确”,在禁忌一栏也只是标出了“孕妇禁用”,除此之外并未见其它提示。

“任何药物的使用都应该在规定的剂量范围内,这或许就是国家药监局此次修订要求注意事项中添加详细使用说明的原因,即当使用时出现不良反应时,应停药并及时就医,应按照药品说明书规定的适应症及用法用量使用,不宜长期用药。” 童培建解释。

另外根据药品不良反应中心收集的案例,此次修订除了取消原说明书中“不良反应尚不明确”的说法,还新增加消化系统、神经精神系统、血管系统等方面的不良反应,同时明确提出婴幼儿禁用。

万通筋骨片不是万通筋骨贴

此次修订方案一出,很多人第一时间想到的却是万通药业的另一款产品,万通筋骨贴,“痛痛痛、贴贴贴”这句熟悉的广告词就来源这款产品。事实上,尽管名字只有一字之差,两者存在本质差别。

万通筋骨片的批准文号是“国药准字”,属于处方药,而查阅万通药业官网发现,万通筋骨贴的批准文则是“健”字号,属于保健品,附带远红外或磁疗功能的万通筋骨贴,属于医疗器械。

童培建主任提醒,虽然外用贴剂造药物主要透过皮肤发挥局部镇痛效果,吸收进入全身的药物量较少,安全性相对来说要更高一些,但造成腰腿疼痛的原因很多,比如肾结石、肾脏肿瘤、癌等都可能引起腰痛,岂是一剂贴膏剂就都能解决的?患者如果出现了长期腰腿疼痛的情况不要讳疾忌医,要及时去医院诊断,采取相应的治疗方式,以免贻误病情。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1301615, encodeId=6d0c130161585, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Sep 26 07:49:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507187, encodeId=b61d150e1878e, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Wed Sep 26 07:49:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346491, encodeId=f92b34649138, content=不错的文章值得我有, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Sep 24 22:19:37 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346480, encodeId=0c11346480b6, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Sep 24 20:25:42 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346467, encodeId=270134646e87, content=中成药的不良反应更应加强监管, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er1NWicAJXsydibubSKuN77NyfRL14esbMEW21KjkUgPpWx0j1Oib7qTe1uY8JkBh45epQEp1V3feqVQ/132, createdBy=ee8e2448391, createdName=玏儿, createdTime=Mon Sep 24 18:10:21 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346457, encodeId=acff34645e48, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Mon Sep 24 17:06:28 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
    2018-09-26 xuyu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1301615, encodeId=6d0c130161585, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Sep 26 07:49:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507187, encodeId=b61d150e1878e, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Wed Sep 26 07:49:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346491, encodeId=f92b34649138, content=不错的文章值得我有, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Sep 24 22:19:37 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346480, encodeId=0c11346480b6, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Sep 24 20:25:42 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346467, encodeId=270134646e87, content=中成药的不良反应更应加强监管, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er1NWicAJXsydibubSKuN77NyfRL14esbMEW21KjkUgPpWx0j1Oib7qTe1uY8JkBh45epQEp1V3feqVQ/132, createdBy=ee8e2448391, createdName=玏儿, createdTime=Mon Sep 24 18:10:21 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346457, encodeId=acff34645e48, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Mon Sep 24 17:06:28 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1301615, encodeId=6d0c130161585, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Sep 26 07:49:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507187, encodeId=b61d150e1878e, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Wed Sep 26 07:49:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346491, encodeId=f92b34649138, content=不错的文章值得我有, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Sep 24 22:19:37 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346480, encodeId=0c11346480b6, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Sep 24 20:25:42 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346467, encodeId=270134646e87, content=中成药的不良反应更应加强监管, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er1NWicAJXsydibubSKuN77NyfRL14esbMEW21KjkUgPpWx0j1Oib7qTe1uY8JkBh45epQEp1V3feqVQ/132, createdBy=ee8e2448391, createdName=玏儿, createdTime=Mon Sep 24 18:10:21 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346457, encodeId=acff34645e48, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Mon Sep 24 17:06:28 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
    2018-09-24 1e1b8538m79(暂无匿称)

    不错的文章值得我有

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1301615, encodeId=6d0c130161585, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Sep 26 07:49:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507187, encodeId=b61d150e1878e, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Wed Sep 26 07:49:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346491, encodeId=f92b34649138, content=不错的文章值得我有, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Sep 24 22:19:37 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346480, encodeId=0c11346480b6, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Sep 24 20:25:42 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346467, encodeId=270134646e87, content=中成药的不良反应更应加强监管, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er1NWicAJXsydibubSKuN77NyfRL14esbMEW21KjkUgPpWx0j1Oib7qTe1uY8JkBh45epQEp1V3feqVQ/132, createdBy=ee8e2448391, createdName=玏儿, createdTime=Mon Sep 24 18:10:21 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346457, encodeId=acff34645e48, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Mon Sep 24 17:06:28 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
    2018-09-24 天地飞扬

    了解一下,谢谢分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1301615, encodeId=6d0c130161585, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Sep 26 07:49:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507187, encodeId=b61d150e1878e, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Wed Sep 26 07:49:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346491, encodeId=f92b34649138, content=不错的文章值得我有, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Sep 24 22:19:37 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346480, encodeId=0c11346480b6, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Sep 24 20:25:42 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346467, encodeId=270134646e87, content=中成药的不良反应更应加强监管, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er1NWicAJXsydibubSKuN77NyfRL14esbMEW21KjkUgPpWx0j1Oib7qTe1uY8JkBh45epQEp1V3feqVQ/132, createdBy=ee8e2448391, createdName=玏儿, createdTime=Mon Sep 24 18:10:21 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346457, encodeId=acff34645e48, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Mon Sep 24 17:06:28 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
    2018-09-24 玏儿

    中成药的不良反应更应加强监管

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1301615, encodeId=6d0c130161585, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Sep 26 07:49:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507187, encodeId=b61d150e1878e, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Wed Sep 26 07:49:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346491, encodeId=f92b34649138, content=不错的文章值得我有, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Sep 24 22:19:37 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346480, encodeId=0c11346480b6, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Sep 24 20:25:42 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346467, encodeId=270134646e87, content=中成药的不良反应更应加强监管, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er1NWicAJXsydibubSKuN77NyfRL14esbMEW21KjkUgPpWx0j1Oib7qTe1uY8JkBh45epQEp1V3feqVQ/132, createdBy=ee8e2448391, createdName=玏儿, createdTime=Mon Sep 24 18:10:21 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346457, encodeId=acff34645e48, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Mon Sep 24 17:06:28 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
    2018-09-24 惠映实验室

    学习了,谢谢分享。

    0

相关资讯

国家药监局深夜开会 说了六点

8月16日晚,国家药品监督管理局紧急召开干部大会,传达中共中央政治局常务委员会会议关于吉林长春长生公司问题疫苗案件调查处理的决定。市场监管总局局长张茅,国家药监局党组书记、副局长李利,局长焦红出席会议并讲话,局机关司局和直属单位负责人参加会议。会议要求,全局机关各司局、各直属单位党组织和全体干部职工要深刻学习领会和坚决贯彻落实习近平总书记重要指示精神,提高政治站位,牢固树立“四个意识”,按照“四

国家药监局:临床急需的罕见病和儿童用药依库珠单抗获批上市

近日,国家药品监督管理局批准依库珠单抗注射液(英文名:Eculizumab Injection)进口注册申请,用于治疗成人和儿童阵发性睡眠性血红蛋白尿症(PNH)和非典型溶血性尿毒症综合征(aHUS)。阵发性睡眠性血红蛋白尿症(PNH)是一种血细胞表面内源性补体抑制物的获得性造血干细胞克隆性疾病;非典型溶血性尿毒症综合征(aHUS)与遗传性或获得性的补体途径失调相关。PNH和aHUS属于全球罕见

国家药监局给提地位 执业药师可参评职称

继国家卫健委给予药师审核处方权后,国家药监局又为执业药师提升地位。8月22日,国家药监局发布《执业药师职业资格制度规定(征求意见稿)》(下称《规定》),《规定》指出,通过全国统一考试,并取得《执业药师职业资格证书》的人员,且符合职称评审相应条件的,视为具备主管药师或主管中药师职称。执业药师实行注册制度、通过考试即为主管药师、执业药师要参加继续教育、“挂证”行为被严厉打击……随着执业药师专业技术价

药监局余震不断:大批司长、副司长被免职!

8月18日,国家市场监督管理总局官网发布消息,针对疫苗案,继续追查原食药总局、国家药监局内部失责人员,从严处理,对一批司长、副司长级官员予以免职。

国家药监局发文 中药饮片要大整治!

国家药监局印发《中药饮片质量集中整治工作方案》,决定在全国范围内开展为期一年的中药饮片质量集中整治。

加入ICH后 又一指导原则向社会征求意见

为规范持有人不良反应监测与报告工作,落实持有人直接报告不良反应主体责任,遵循国际人用药品注册技术协调会(ICH)指导原则相关规定,国家药品监督管理局起草了《个例药品不良反应收集和报告指导原则(征求意见稿)》,现向社会公开征求意见。请于2018年9月20日前将有关意见以电子邮件形式反馈至国家药品监督管理局(原药品化妆品监管司)。

Baidu
map
Baidu
map
Baidu
map